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 Introduction 
 Sarcoidosis, a multisystem disease characterized by 
noncaseating granulomas predominantly affecting the 
lungs, is not uncommon in Northern European coun-
tries, with an annual incidence of 5–40 per 100,000  [1] . 
The etiology of sarcoidosis remains unknown, but an au-
toimmune reaction that is triggered by a pathogen (not 
yet known) in genetically predisposed individuals is the 
most likely cause. Neurosarcoidosis refers to disease 
manifestation of sarcoidosis within the nervous system. It 
is clinically apparent in 5–10% of patients, but has been 
demonstrated in up to 25% of sarcoidosis patients at au-
topsy  [2–4] . The histopathological presentation of neuro-
sarcoidosis is either the pathognomonic noncaseating 
granuloma with lymphomonuclear infiltrates and multi-
nuclear macrophages, or an infiltration of inflammatory 
cells into the meninges or extracellular spaces causing mi-
crovascular damage and diffuse white matter lesions  [5–
7] . Neurological symptoms may range from basal menin-
gitis with cranial nerve involvement to limb paralysis or 
seizures due to a granulomatous lesion or even slowly 
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 Abstract 
 The involvement of the central nervous system in sarcoidosis 
can manifest with a variety of neurological symptoms, most 
of them nonspecific. We identified 13 patients with neurosar-
coidosis diagnosed at our clinic. Six of 13 patients present-
ed  with clinically isolated neurosarcoidosis (CINS) without 
signs or symptoms of systemic disease. CINS patients were 
not different with respect to age, as well as imaging and 
 spinal fluid findings, or disease course. However, we found 
spinal cord involvement in neurosarcoidosis patients much 
more common than previously described (in 8 out of 13 pa-
tients). Spinal cord affection was associated with older age at 
diagnosis and a less favorable response to therapy. Based on 
our findings, we propose a diagnostic path for neurosarcoid-
osis, including spinal magnetic resonance imaging (MRI) as 
a mandatory and early step during diagnostic workup. 
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progressive cognitive decline  [8] . Due to the variability of 
symptoms, neurosarcoidosis is a diagnostic challenge. 
Furthermore, there are currently no unambiguous (imag-
ing or laboratory) parameters to aid in the diagnosis.
 We here report on 13 neurosarcoidosis cases from our 
institution with the typical manifold neurological symp-
tomatology. Based on our experience, we recommend a 
diagnostic path to aid in identifying the disease.
 Patients and Methods 
 We searched the clinical database of the Department of Neurol-
ogy at the University Hospital Zurich for all patients that were 
seen with suspected neurosarcoidosis since 2000. All cases with a 
diagnostic certainty of at least ‘possible neurosarcoidosis’  [9] 
were included. ‘Possible neurosarcoidosis’ was defined as clinical 
condition and neurodiagnostic workup consistent with neurosar-
coidosis, but without histological evidence. For ‘probable neurosar-
coidosis’, typical laboratory findings including cerebrospinal fluid 
(CSF) abnormalities (elevated levels of CSF protein and/or cells, 
presence of oligoclonal bands) and/or histological evidence of sys-
temic disease had to be present in addition to the clinical and neu-
rodiagnostic findings compatible with neurosarcoidosis, while the 
diagnosis of ‘definite neurosarcoidosis’ required proof by a nervous 
system biopsy. Patient charts were reviewed and clinical character-
istics, imaging findings, results of laboratory tests, as well as treat-
ment and outcome were recorded. Comparisons between groups 
were done using a two-sided  t test. Furthermore, a Medline search 
for ‘spinal cord sarcoidosis’ was performed and all studies from 
1994 onwards reporting more than one case of spinal cord sarcoid-
osis were identified. All papers reporting clinical outcome or spinal 
cord MRI data were included for the analysis in  table 3 .
 Results 
 Patient Characteristics 
 Thirteen patients were diagnosed with neurosarcoid-
osis between 2000 and 2014, of those 1 with possible, 11 
with probable, and 1 with definite neurosarcoidosis. Pa-
tient characteristics are shown in  table 1 . The mean age at 
Table 1.  Clinical characteristics of patients with neurosarcoidosis
Patient
no./sex
Age,
years
Neurological symptoms
(presenting, y/n)
Systemic
symptoms
cMRI sMRI LP Treatment Clinical course 
(follow up, m)
 1/M** 35 Cranial neuritis (y) + + n.d. + Steroids + MTX better (40)
 2/M** 49 Headache, focal seizure (n) + + + – Steroids stable (30)
 3/M** 57 Meningitis, optic neuritis, 
headache, gait disturbance (n)
+ + + + Steroids, steroids + MTX,
steroids 
worse (39)
 4/F* 38 Headache, facial hypoesthesia (y) + + – + Steroids, stopped after 24 m better (41)
 5/F** 46 Paraplegia (Myelitis) (n) + – + + Steroids + MTX died (37)
 6/F** 27 Polyneuritis (y) + – n.d. + None better (33)
 7/F*** 31 Optic neuritis (y) + + + + Steroids for 144 m, MTX 
monotherapy since 24 m
worse (169)
 8/M** 48 Basal meningitis, radiculopathy (y) – + + + 2 Steroid courses for overall 
7 m, stopped since 21 m
better (37)
 9/F** 60 Slowly progressive tetraparesis (y) – – + – Steroids + azathioprine better (19)
10/M* 20 Basal meningitis (y) – + n.d. + Steroids + mycophenolate stable (204)
11/F** 38 Progressive left paresis/radiculitis (y) – – + + Steroids 17 m, MTX 3 m 
stopped due to stabilization of 
disease, infliximab 3 m, MTX 
13 m, Rituximab 6 m, tocili-
zumab 3 m, steroids
worse (62)
12/M** 52 Basal meningitis (y) – + n.d. + Steroids stable (2)
13/M** 51 Tetraparesis (y) – – + + Steroids stable (4)
 Diagnostic certainty: Neurosarcoidosis possible*, probable**, certain***. + = Pathological findings; – = normal; n.d. = not done. 
cMRI = cranial MRI; sMRI = MRI of the spine; LP = lumbar puncture results; MTX = methotrexate; m = months.
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the onset of neurological symptoms was 42.5 years (range 
20–60 years), with a male:female ratio of close to 1: 1. The 
median follow-up was 37 months. Seven patients dis-
played clinical signs of systemic sarcoidosis before or at 
the time of presentation for neurological workup, 6 with 
pulmonary disease and 1 with cardiac arrhythmia that led 
to further diagnostic workup and was attributed to sar-
coidosis. Four of these 7 patients presented initially with 
neurological symptoms, but were diagnosed only after 
the occurrence of systemic signs. The remaining 6 pa-
tients were diagnosed only based on neurological symp-
toms (P8–13 in  table 1 ), and will be referred to as clini-
cally isolated neurosarcoidosis (CINS). CSF was abnor-
mal in 12 of 13 cases with findings ranging from mild 
pleocytosis to substantial elevation in protein content, 
positive oligoclonal bands, and/or increased levels of sol-
uble interleukin 2 receptor alpha chain (CD25) ( tables 1 
and  2 ).
 Neuropathy was suspected in one patient who report-
ed a tingling sensation in both lower legs. ENMG was un-
remarkable in this case. In two patients, one of them only 
several years after diagnosis of neurosarcoidosis and im-
munosuppressive treatment, ENMG revealed a begin-
ning axonal peripheral neuropathy.
 Except for one case (P6) with rapid spontaneous clin-
ical improvement, all patients received immunosuppres-
sive/anti-inflammatory therapies, either with steroids 
alone (P2, P4, P8, P12, P13) at an earlier stage of treat-
ment with rather short follow-up: median 30 months; 
steroids in combination with methotrexate (MTX): P1, 
P3, P5 with a median follow-up of 39 months, or in com-
bination with other drugs: azathioprine (P9), mycophe-
nolate (P10), or monotherapy with MTX (P7). One pa-
tient with severe disease progression was switched from 
steroids to MTX and later to infliximab and tocilizumab, 
without achieving sufficient control of symptoms (P11). 
Overall, the clinical course was good (neurological signs/
symptoms stable or better) in 9 patients and progressive 
(worsening of signs/symptoms) in 4; one patient died 
following long-term steroid therapy and immobiliza-
tion.
 Imaging Findings 
 MRI of the brain was abnormal in 8 cases and normal 
in 5. MRI of the spinal cord was pathological in 8 cases, 
not done in 4 cases and normal in only 1 patient ( table 1 ). 
Both, spinal and cerebral imaging findings were present 
in 5 patients. Patients with spinal cord involvement tend-
Table 2.  Imaging and spinal fluid/serum findings in patients with neurosarcoidosis
Criteria CINS (n = 6) Neurosarcoidosis with systemic signs (n = 7)
Age at diagnosis, years 44.8±14.1 40.4±10.7
Presenting symptoms neurological 6 4
Imaging findings (out of n)
MRI: spinal 4 (4) 4 (4)
Meningeal enhancement 1 1
Solitary lesion (s) 1 1
T2/FLAIR- hyperintensities 2 2
MRI: cerebral 3 (6) 5 (7)
Meningeal enhancement 3 0
Solitary lesions (s) 0 2
T2/FLAIR- hyperintensities 0 3
MRI: spinal and cerebral findings 1 3
Positive chest X-ray 0 5
Spinal fluid findings (out of n)
Increased cell count (/μl) 4 (6) (range 34–273) 2 (7) (range 10–76)
Increased protein (mg/l) 5 (6) (range 436–3,940) 4 (7) (range 506–2,600)
Glucose 2 decreased (6) 2 decreased, 1 increased (7)
Increased lactate 2 (6) 1 (7)
Positive oligoclonal bands 4 (6) 2 (5)
Positive IgG Index 3 (6) 3 (5)
Positive IgA Index 1 (6) 1 (5)
Positive IgM Index 0 (6) 1 (5)
Increased sIL2 receptor (pg/ml) 3 (6) (range 184–426) 1 (1) (439)
ACE elevation (serum) 0 (5) 1 (2)
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ed to be older (48.8 ± 9.2 vs. 36.2 ± 5.1 years, p = 0.06) and 
had a less favorable response to therapy (p = 0.01).
 We further classified MRI patterns of neurosarcoid-
osis into a) meningeal contrast enhancement, b) solitary 
lesions, or c) predominantly subcortical T2/FLAIR hy-
perintensities with nonspecific appearance ( table 2 and 
 fig. 1 ). These three patterns could be discerned on MRI of 
the brain as well as the spine. All of the solitary spinal le-
sions/T2 hyperintensities (n = 6) were located in the cer-
vical or thoracic spine.
 Chest X-ray did not show any abnormalities in patients 
with CINS, but was positive in 5 out of the remaining 7 pa-
tients with systemic symptoms ( table 2 ). In 4 out of the 6 
CINS patients, FDG-PET was performed to search for a bi-
opsy site, which was successful in all 4. In 3 of these patients, 
the histological confirmation of sarcoidosis was based on 
biopsy results from FDG-enhancing sites revealed by PET.
 Discussion 
 To reach the diagnosis of definite or at least probable 
neurosarcoidosis, a biopsy must be obtained to demon-
strate the typical histological picture of sarcoidosis either 
in the nervous system (definite) or another affected organ 
along with imaging and laboratory signs suggestive of 
neurosarcoidosis (probable neurosarcoidosis). In pa-
tients with known systemic sarcoidosis and neurological 
symptoms that remain otherwise unexplained, the suspi-
cion of neurosarcoidosis is high. The diagnostic path for 
this scenario is focused on the collection of evidence for 
CNS involvement by clinical examination, MRI, and CSF 
studies ( fig. 2 ). It is now established that neither serum 
 Fig. 1. Neurosarcoidosis imaging patterns. Characteristic MRI find-
ings in neurosarcoidosis patients:  (a ) T2/ FLAIR hyperintensities 
without contrast enhancement,  (b ) brain solitary, contrast enhancing 
lesion (arrow),  (c ) meningeal and diffuse parenchymal contrast en-
hancement (arrows), and  (d ) spinal cord solitary contrast enhancing 
lesion (upper panel: T2w image, lower panel: T1 post contrast image). 
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Neurological symptoms consistent with neurosarcoidosis
Collect evidence for neurosarcoidosis
Physical/neurological examination
Imaging: MRI brain and spine
CSF: cell count, protein, IgA, IgM, IgG indices,
oligoclonal bands, sIL2-receptor
Systemic sarcoidosis present?
Yes No
CINS
Collect evidence for systemic
sarcoidosis
Chest X-ray/chest CT
Determine site for biopsy
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If CNS lesion/meningeal enhancement present and risk acceptable:
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nor spinal fluid angiotensin converting enzyme (ACE) 
levels are helpful for the diagnosis of neurosarcoidosis 
(sensitivity of 24–55% for CSF levels)  [10, 11] . CSF analy-
sis should include glucose, lactate, protein, number and 
types of cells and antibody indices (IgM, IgA, IgG) since 
these parameters may correlate with disease activity  [12] . 
However, depending on the MRI-defined disease exten-
sion (e.g., diffuse leptomeningeal enhancement versus 
solitary lesions) and disease activity, CSF parameters 
might be normal in approximately 40% of cases  [12] . Oli-
goclonal bands were positive only in 22% of cases with 
probable or definite neurosarcoidosis  [12] . Spinal fluid 
quantification of soluble CSF interleukin 2 receptor alpha 
chain, a marker of T-cell activation, appears suitable in 
the diagnostic workup for neurosarcoidosis, since levels 
above 150 pg/ml allow to discriminate neurosarcoidosis 
from other differential diagnoses such as multiple sclero-
sis and vasculitis as well as healthy controls with an over-
all accuracy of 93% (sensitivity of 61% and specificity of 
93%)  [13] . While activated CD4+ T- cells are the hallmark 
of the sarcoid granuloma immunopathogenesis and the 
CD4/CD8 T-cell ratio typically increased in bronchoal-
veolar lavage of sarcoidosis patients, the diagnostic utility 
of this test for neurosarcoidosis remains uncertain. In a 
previous case series of 8 patients, it was increased only in 
three and normal in five  [14–16] . Sarcoid-induced neu-
ropathy is rare, but may be a presenting symptom of neu-
rosarcoidosis  [3, 17–19] . ENMG, albeit not specific for 
neurosarcoidosis, is certainly of value in cases in which 
symptoms of neuropathy or myopathy are reported and 
Table 3.  Summary of studies reporting spinal cord affection in neurosarcoidosis
Study Spinal cord affection of
neurosarc oidosis patients,
n/n (%)
Spinal cord level affected, 
n
Outcome, 
n
Christoforidis et al. [27], 1999 8/38 (21) 4 cervical; 1 thoracic;
3 lumbal
3 improved; 4 stable or worse;
1 unknown
Joseph and Scolding [28], 2008 5/30 (17) – 5 worse
Lexa et al. [29], 1994 4/24 (17) – 4 stable/improved radiologically
(no clinical outcome reported)
Marangoni et al. [11], 2006 3/7 (43) 2 cervical; 1 thoracic 2 improved; 1 worse/died
Nozaki et al. [7], 2012 17/70 (24) 17 with positive spinal MRI
(affected levels not reported)
–
Sakushima et al. [21], 2011 6/17 (35) 6 cervical 3 stable/improved; 3 worse
Sharma [30], 1997 1/38 (3) all segments 1 improved
Spencer et al. [31], 2004 9/21 (43) 8 cervical; 1 thoracic 7 improved; 2 worse
Zajicek et al. [9], 1999 19/68 (28) 11 with positive spinal MRI
(affected levels not reported)
6 stable/improved; 13 worse
Reports of selected cases with spinal cord sarcoidosis
Cohen-Aubart et al. [32], 2010 31/31 (100) 15 cervical; 17 thoracic;
6 lumbosacral
11 improved; 17 worse;
3 unknown
Kobayashi et al. [33], 2013 9/9 (100) 4 cervical; 3 thoracic; 
1 lumbar; 1 all segments
8 improved; 1 stable
Saleh et al. [34], 2006 8 (100) retrospective 4 cervical; 4 thoracic 6 improved; 2 worse
Sohn et al. [20], 2014 27/27 (100) 21 cervical; 18 thoracic;
10 lumbosacral
–
Varron et al. [23], 2009 7/7 (100) 4 cervical; 2 lumbosacral;
1 whole spinal cord
3 stable; 1 improved; 1 worse;
2 unknown
Not reported: ‘–’.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
25
/2
01
6 
3:
12
:0
0 
PM
 Wegener/Linnebank/Martin/Valavanis/
Weller 
 Eur Neurol 2015;73:71–77
DOI: 10.1159/000366199
76
for diagnosis and follow up of therapy-induced myopathy 
or neuropathy. Besides the above-mentioned diagnostic 
parameters, neuroimaging with MRI remains an essential 
part of the diagnostic workup for neurosarcoidosis. The 
MRI protocol should include high resolution T2 and 
FLAIR images for detection of edema or white matter 
changes, as well as pre- and post-contrast T1, to reveal 
even subtle meningeal contrast enhancement. To dis-
criminate vascular pathologies or microbleeds, MRA and 
susceptibility-weighted (T2 * ) imaging  should also be per-
formed.
 The prevalence of spinal cord lesions on MRI in our 
patient cohort was high (62%). Previous reports estimat-
ed the prevalence of spinal cord neurosarcoidosis to be 
about 1% of all sarcoidosis patients, or between 3 and 43% 
of neurosarcoidosis patients ( table  3 )  [20–22] . We as-
sume that spinal cord involvement is often missed, either 
due to unspecific symptoms that might be related to cord 
involvement such as sensory disturbances or because it 
was clinically silent. The cervical spine is most frequently 
affected; however, all spinal cord levels may reveal disease 
activity ( table  3 ). Identification of spinal cord involve-
ment is important, since it might indicate patients with a 
more protracted disease course requiring earlier start of 
nonsteroidal therapies  [21, 23, 24] . While our case series 
supports a more unfavorable clinical course when the spi-
nal cord is affected, it is interesting to note that clinical 
outcome data of previous studies in this subgroup of pa-
tients are actually less clear ( table 3 ). Due to the signifi-
cant prevalence of spinal cord involvement, we suggest 
that spinal MRI should be included in the routine workup 
of neurosarcoidosis. Since the course of treatment may 
last for prolonged periods of time, imaging evidence of 
disease activity is highly important and can also monitor 
treatment efficacy. A CNS biopsy should be undertaken 
to clear all doubts, if any.
 Due to the rarity of the disease and the small sample 
size of this retrospective study, interpretation of our find-
ings is limited. However, based on our experience, we 
suggest the following diagnostic path for patients with 
suspected neurosarcoidosis.
 In the case of a patient presenting with neurological 
symptoms consistent with neurosarcoidosis, but no fur-
ther clinical evidence of systemic sarcoidosis ( fig. 2 , right 
side), searching for systemic disease manifestations is the 
first step. One aspect is that subclinical systemic disease 
should be recognized; another is that a biopsy site might 
be found. Routine workup for systemic involvement 
should include a chest-CT scan, and, if doubts remain, 
 [18 F]-fluorodeoxyglucose-positron emission tomogra-
phy, as it might be more sensitive to reveal a suspicious 
lymph node that is accessible at minimal procedural risk 
 [25, 26] .
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